NCT00001512View on ClinicalTrials.gov

Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 9, 1996

Primary Completion Date

March 5, 2010

Study Completion Date

March 5, 2010

Conditions
B Cell LymphomaFollicular LymphomaLymphoma
Interventions
DRUG

Id-KLH Vaccine

DRUG

GM-CSF

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00001512 - Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines | Biotech Hunter | Biotech Hunter